Abbott Laboratories news

   Watch this stock
Showing stories 1 - 10 of about 107   

Articles published

ABT 44.45 +0.78 (1.79%)
price chart
Abbott Laboratories (ABT) Chairman and CEO Miles D White Bought $777216 of Stocks
Abbott Laboratories discovers, develops, manufactures and sells health care products. Its products include branded generic pharmaceuticals manufactured internationally, marketed and sold outside the United States.
Revenue Update on Abbott Laboratories(NYSE:ABT)  Trade Calls
Insider Trading and Recommendation Review: Abbott Laboratories (NYSE:ABT)  Post Registrar
Abbott has more reason to walk away from Alere deal
There's more evidence that Abbott Laboratories' pursuit of Alere, a health care diagnostics company, may have been a bad idea.
Argus Says Abbott Laboratories Shares Favorably Valued Despite ' ...  Benzinga
Attentive Stocks in Active Notes- ServiceNow, Inc. (NYSE:NOW), Abbott ...  Seneca Globe
New Challenges In Alere Inc (NYSE:ALR) - Abbott Laboratories (NYSE:ABT)'s ...
Alere Inc (NYSE:ALR) has been facing a number of problems including a delayed merger with Abbott Laboratories (NYSE:ABT), with the newest of these problems being a new class-action lawsuit filed over a new blood coagulation test that was recalled due ...
Abbott Results, Helped by Product Launches, Top Views
In Abbott's diagnostics segment, revenue climbed 4.1% to $1.23 billion, or a 6% increase in operational revenue, as sales rose in its core laboratory, molecular and point of care divisions. Established pharmaceuticals sales edged up 0.4%, or 9.5% on ...
Focus On Abbott Labs Remains On Pending Deals  Benzinga
Abbott sales beat on higher demand for medical devices  Reuters
Abbott Laboratories Avoids a 'Sell' Rating from Analysts
In this final part of our series, we'll take a look at Wall Street analyst recommendations and target prices for Abbott Laboratories' (ABT) stock over the next year. Based on the recommendations of 21 brokerage firms in a Bloomberg survey, 71% of them ...
Abbott Laboratories (ABT) Stock Slumps Despite FDA Approval
NEW YORK (TheStreet) -- Abbott Laboratories (ABT) has won FDA approval for a new stent that can be absorbed into the bloodstream after implantation.
New Abbott stent, which dissolves in blood vessel, gets FDA approval  Chicago Tribune
Abbott Labs' Absorb Stent Gets Regulatory Approval in U.S.
Abbott Labs Earnings Top On Medical Devices; St. Jude Meets Profit Views
Abbott Laboratories (ABT) said second-quarter profit topped analysts' estimates on rising demand across all four of its business segments, with medical devices, a recent underperformer, leading the way.
Abbott Labs (ABT) Stock Rising on Q2 Earnings Beat
What to Look for When Abbott Labs (ABT) Reports Q2 Earnings
"For 2016, Abbott is likely to continue to drive meaningful positive operating leverage with potentially modest sales growth acceleration as the company absorbs pending acquisitions including Alere (ALR) and St. Jude's Medical (STJ)," Leerink wrote in ...
PepsiCo, Inc. (NYSE:PEP) & Abbott Laboratories (NYSE:ABT) Worth Watching ...  Money News (press release)
Recent Product Launches Drive Growth For Abbott Laboratories In Q2'16
Nevertheless, Abbott's operational growth was better as compared to its growth in the last few quarters. The company's vascular business saw encouraging growth driven by the strong adoption of Mitraclip for the treatment of mitral regurgitation.
Abbott Laboratories (NYSE:ABT) Updates On AlereInc (NYSE:ALR), St. Jude ...
Abbott Laboratories (NYSE:ABT) has given updates regarding its $5.80 billion and $25 billion deals with Alere Inc (NYSE:ALR) and St. Jude Medical, Inc. (NYSE:STJ), respectively, during a conference call that followed its second quarter earnings report ...